{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T07:51:45Z","timestamp":1778917905923,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,12,18]],"date-time":"2014-12-18T00:00:00Z","timestamp":1418860800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s10067-014-2842-5","type":"journal-article","created":{"date-parts":[[2014,12,17]],"date-time":"2014-12-17T03:35:15Z","timestamp":1418787315000},"page":"427-431","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Assessment of tuberculosis infection during treatment with biologic agents in a BCG-vaccinated pediatric population"],"prefix":"10.1007","volume":"35","author":[{"given":"Basak Yildiz","family":"Atikan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cengiz","family":"Cavusoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merve","family":"Dortkardesler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betul","family":"Sozeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,18]]},"reference":[{"issue":"15","key":"2842_CR1","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15):1098\u20131104","journal-title":"N Engl J Med"},{"key":"2842_CR2","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","volume":"48","author":"JJ Gomez-Reino","year":"2003","unstructured":"Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48:2122\u20132127","journal-title":"Arthritis Rheum"},{"key":"2842_CR3","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1473-3099(08)70227-5","volume":"8","author":"RS Wallis","year":"2008","unstructured":"Wallis RS (2008) Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 8:601\u2013611","journal-title":"Lancet Infect Dis"},{"key":"2842_CR4","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1093\/ndt\/gfl416","volume":"21","author":"U Sester","year":"2006","unstructured":"Sester U, Junker H, Hodapp T, Sch\u00fctz A, Thiele B, Meyerhans A et al (2006) Improved efficiency in detecting cellular immunity towards M. tuberculosis in patients receiving immunosuppressive drug therapy. Nephrol Dial Transpl 21:3258\u20133268","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"2842_CR5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","volume":"63","author":"T Beukelman","year":"2011","unstructured":"Beukelman T, Patkar NM, Saag KG et al (2011) American college of rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 63(4):465\u2013482","journal-title":"Arthritis Care Res"},{"issue":"3","key":"2842_CR6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1086\/421494","volume":"39","author":"AK Mohan","year":"2004","unstructured":"Mohan AK, Cot\u00e9 TR, Block JA, Manadan AM, Siegel JN, Braun MM (2004) Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 39(3):295\u2013299","journal-title":"Clin Infect Dis"},{"key":"2842_CR7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3899\/jrheum.140103","volume":"91","author":"F Cantini","year":"2014","unstructured":"Cantini F, Niccoli L, Goletti D (2014) Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-\u03b1 (TNF-\u03b1) targeted biologics and recently licensed TNF-\u03b1 inhibitors: data from clinical trials and national registries. J Rheumatol Suppl 91:56\u201364","journal-title":"J Rheumatol Suppl"},{"key":"2842_CR8","unstructured":"Zu\u00f1iga D, Torres-Garc\u00eda T, Santos-Mendoza TS, Rodriguez-Reyna J, Granados EJ (2012) Yunis Cellular and humoral mechanisms involved in the control of tuberculosis Clin Dev Immunol, p. 193923"},{"key":"2842_CR9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1475-2840-13-94","volume":"13","author":"C Howard","year":"2014","unstructured":"Howard C, Noe A, Skerjanec A, Holzhauer B, Wernsing M, Ligueros-Saylan M et al (2014) Safety and tolerability of canakinumab, an IL-1\u03b2 inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies. Cardiovasc Diabetol 13:94","journal-title":"Cardiovasc Diabetol"},{"key":"2842_CR10","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/thx.2005.046797","volume":"60","author":"British Thoracic Society Standards of Care Committee","year":"2005","unstructured":"British Thoracic Society Standards of Care Committee (2005) BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 60:800\u2013805","journal-title":"Thorax"},{"key":"2842_CR11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1164\/ajrccm.161.supplement_3.ats600","volume":"161","author":"American Thoracic Society","year":"2000","unstructured":"American Thoracic Society (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161:221\u2013247","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2842_CR12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1164\/rccm.200402-232OC","volume":"70","author":"I Brock","year":"2004","unstructured":"Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P (2004) Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 70(1):65\u201369","journal-title":"Am J Respir Crit Care Med"},{"issue":"RR05","key":"2842_CR13","first-page":"1","volume":"59","author":"GH Mazurek","year":"2010","unstructured":"Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K (2010) Division of tuberculosis elimination, national center for HIV, STD, and TB prevention, CDC. Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection. MMWR 59(RR05):1\u201325","journal-title":"MMWR"},{"issue":"4","key":"2842_CR14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/BOR.0b013e3283474d62","volume":"23","author":"R Smith","year":"2011","unstructured":"Smith R, Cattamanchi A, Steingart KR, Denkinger C, Dheda K, Winthrop KL, Pai M (2011) Interferon-\u03b3 release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders. Curr Opin Rheumatol 23(4):377\u2013384","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"2842_CR15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/archdischild-2013-303641","volume":"98","author":"L Pollock","year":"2013","unstructured":"Pollock L, Basu Roy R, Kampmann B (2013) How to use: interferon \u03b3 release assays for tuberculosis. Arch Dis Child Educ Pract Ed 98(3):99\u2013105","journal-title":"Arch Dis Child Educ Pract Ed"},{"issue":"12","key":"2842_CR16","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1097\/INF.0b013e318269d10c","volume":"31","author":"DI Ling","year":"2012","unstructured":"Ling DI, Cr\u00e9peau CA, Dufresne M, Khan S, Quach C, Dendukuri N et al (2012) Evaluation of the impact of interferon-gamma release assays on the management of childhood tuberculosis. Pediatr Infect Dis J 31(12):1258\u20131262","journal-title":"Pediatr Infect Dis J"},{"key":"2842_CR17","unstructured":"American Academy of Pediatrics. Tuberculosis. In: Red Book: (2012) Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012"},{"issue":"6","key":"2842_CR18","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","volume":"52","author":"L Carmona","year":"2005","unstructured":"Carmona L, Go\u00b4mez-Reino JJ, Valverde VR et al (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthiritis Rheumatism 52(6):1766\u20131772","journal-title":"Arthiritis Rheumatism"},{"key":"2842_CR19","doi-asserted-by":"crossref","first-page":"505171","DOI":"10.5402\/2011\/505171","volume":"2011","author":"D Maritsi","year":"2011","unstructured":"Maritsi D, Al-Obadi M, Brogan PA, Eleftheriou D, Dixon GL (2011) The performance of quantiferon TB gold in-tube as a screening tool in paediatric rheumatology prior to initiation of infliximab: a single centre\u2019s experience. ISRN Rheumatology 2011:505171","journal-title":"ISRN Rheumatology"},{"key":"2842_CR20","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s00431-011-1501-y","volume":"170","author":"S Hess","year":"2011","unstructured":"Hess S, Hospach T, Nossal R, Dannecker G, Magdorf K, Uhlemann F (2011) Life-threatening disseminated tuberculosis as a complication of TNF-\u03b1 blockade in an adolescent. Eur J Pediatr 170:1337\u20131342","journal-title":"Eur J Pediatr"},{"key":"2842_CR21","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1007\/s00296-011-2030-8","volume":"32","author":"O Kilic","year":"2012","unstructured":"Kilic O, Kasapcopur O, Camcioglu Y, Cokugras H, Arisoy N, Akcakaya N (2012) Is it safe to use anti-TNF-\u03b1 agents for tuberculosis in children suffering with chronic rheumatic disease? Rheumatol Int 32:2675\u20132679","journal-title":"Rheumatol Int"},{"issue":"9","key":"2842_CR22","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/cid\/cit489","volume":"57","author":"SS Toussi","year":"2013","unstructured":"Toussi SS, Pan N, Walters HM, Walsh TJ (2013) Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor\u2013\u03b1 inhibitors: systematic review of the literature. Clin Infect Dis 57(9):1318\u20131330","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2842_CR23","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.3899\/jrheum.110373","volume":"38","author":"EM Kim","year":"2011","unstructured":"Kim EM, Uhm WS, Bae SC, Yoo DH, Kim TH (2011) Incidence of tuberculosis among Korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers. J Rheumatology 38(10):2218\u20132223","journal-title":"J Rheumatology"},{"issue":"5","key":"2842_CR24","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","volume":"36","author":"I Solovic","year":"2010","unstructured":"Solovic I, Sester M, Gomez-Reino JJ et al (2010) The risk of tuberculosis related to TNF antagonist therapies: a TBNET consensus statement. Eur Respir J 36(5):1185\u20131206","journal-title":"Eur Respir J"},{"issue":"7","key":"2842_CR25","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3899\/jrheum.100623","volume":"38","author":"EC Keystone","year":"2011","unstructured":"Keystone EC, Papp KA, Wobeser W (2011) Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. J Rheumatol 38(7):1234\u20131243","journal-title":"J Rheumatol"},{"issue":"ACS-6","key":"2842_CR26","first-page":"1","volume":"34","author":"Canadian Tuberculosis Committee","year":"2008","unstructured":"Canadian Tuberculosis Committee (2008) Updated recommendations on interferon gamma release assays for latent tuberculosis infection. An advisory committee statement (ACS). Can Commun Dis Rep 34(ACS-6):1\u201313","journal-title":"Can Commun Dis Rep"},{"issue":"RR-6","key":"2842_CR27","first-page":"1","volume":"49","author":"American Thoracic Society","year":"2000","unstructured":"American Thoracic Society (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 49(RR-6):1\u201351","journal-title":"MMWR Recomm Rep"},{"issue":"6","key":"2842_CR28","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.23705","volume":"59","author":"DY Chen","year":"2008","unstructured":"Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL (2008) Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 59(6):800\u2013806","journal-title":"Arthritis Rheum"},{"issue":"12","key":"2842_CR29","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s10067-011-1771-9","volume":"30","author":"B Chang","year":"2011","unstructured":"Chang B, Park HY, Jeon K (2011) Interferon-\u03b3 release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. Clin Rheumatol 30(12):1535\u20131541","journal-title":"Clin Rheumatol"},{"key":"2842_CR30","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10067-009-1334-5","volume":"29","author":"NA Ayaz","year":"2010","unstructured":"Ayaz NA, Demirkaya E, Bilginer Y (2010) Preventing tuberculosis in children receiving anti-TNF treatment. Clin Rheumatol 29:389\u2013392","journal-title":"Clin Rheumatol"},{"key":"2842_CR31","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00296-010-1424-3","volume":"31","author":"T Cagatay","year":"2011","unstructured":"Cagatay T, Kilicaslan Z, Cagatay P et al (2011) TNF-alpha antagonist therapy modify the tuberculin skin test response. Rheumatol Int 31:1147\u20131151","journal-title":"Rheumatol Int"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-014-2842-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-014-2842-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-014-2842-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T08:57:38Z","timestamp":1559120258000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-014-2842-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,18]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["2842"],"URL":"https:\/\/doi.org\/10.1007\/s10067-014-2842-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,18]]}}}